NUCRYST Pharmaceuticals Corp. (NASDAQ:NCST)
Industry: Healthcare
NUCRYST Pharmaceuticals Corp. (NUCRYST), incorporated on December 18, 1997, develops, manufactures and commercializes medical products that fight infection and inflammation. The Company's technology enables it to convert silver's microcrystalline structure into an atomically disordered nanocrystalline coating. The Company produces its nanocrystalline silver as a coating for wound dressing products under the trademark SILCRYST, and as a powder for use as an active pharmaceutical ingredient (API), referred to as NPI 32101. Four advanced wound care products with the Company's SILCRYST coatings have received the United States Food and Drug Administration (FDA) clearance and approval of other regulators for over 30 countries around the world, and are sold by Smith & Nephew plc under its Acticoat trademark. Acticoat products are used for a variety of wound types by hospitals, clinics, burn centers, doctors' offices, home healthcare agencies and nursing homes. The Company is also developing pharmaceutical products to extend its nanocrystalline silver technology to the treatment of dermatological and gastrointestinal conditions. NUCRYST is engaged in Phase II clinical trials of NPI 32101. Smith & Nephew is the Company's only customer for all of its existing products. Acticoat Products with SILCRYST Coatings The Company manufactures four Acticoat products with its SILCRYST coatings that have received FDA clearance: Acticoat 3/Acticoat Burn for wounds requiring up to three days of sustained anti-microbial activity; Acticoat 7 for wounds requiring up to seven days of sustained anti-microbial activity; Acticoat Absorbent for wounds with moderate to heavy excess fluid, or exudate, requiring up to three days of sustained anti-microbial activity, and Acticoat Moisture Control for wounds with light to moderate exudate requiring up to seven days of sustained anti-microbial activity. The Company also works with Smith & Nephew to develop new Acticoat wound care products with its SILCRYST coatings. Along with the anti-microbial and anti-inflammatory effects of Acticoat, Smith & Nephew is promoting the use of Acticoat products with SILCRYST coatings to help reduce the risk of methicillin-resistant staphylococcus aureus (MRSA) transmission. NUCRYST's SILCRYST products have efficacy in controlling MRSA in the laboratory and clinically. Acticoat 3 and Acticoat Burn are used in the in-patient burn segment of the wound dressing market. They consist of a rayon/polyester non-woven core between two layers of high-density polyethylene (HDPE) mesh with SILCRYST coatings that provides an anti-microbial barrier layer to protect wounds. A non-woven inner core retains moisture and improves handling characteristics. Acticoat 7 is used primarily in the chronic wound segment of the wound dressing market. Acticoat 7 provides consistent seven-day sustained anti-microbial protection for patients with venous stasis ulcers, diabetic foot ulcers, pressure ulcers and other persistent wounds, and allows up to seven days before wound dressings are required to be changed. Acticoat 7 consists of two rayon/polyester non-woven inner cores laminated between three layers of HDPE mesh with SILCRYST coatings. The Acticoat Absorbent is used primarily in the chronic wound segment of the wound dressing market. The Acticoat Absorbent Dressing consists of a calcium alginate fabric coated on both sides with SILCRYST nanocrystals. The Acticoat Moisture Control Dressing is a solid foam dressing, and is used primarily in the chronic wound segment of the wound dressing market. The Acticoat Moisture Control Dressing consists of absorbent foam sandwiched between an outer film and a non-adherent wound contact layer with SILCRYST coatings. Pharmaceutical Products The Company's lead pharmaceutical product candidate is a topical cream containing NPI 32101 for the treatment of dermatological conditions, such as atopic dermatitis. In September 2004, it completed a Phase II clinical trial for topical NPI 32101 in 224 adult patients with mild to mod
As Of: 10/07 00:00 ET
*Quotes delayed by 20min.
BuyIns.Net Alerts for Symbol NCST
- No BuyIns.Net Alerts Available for NCST
Graphs for NCST
3 Month Graph
6 Month Graph
1 Year Graph
